Klivira
Request demo

Optimizing Ophthalmology AIM Specialty Health Integration

Klivira streamlines the complex demands of ophthalmology AIM Specialty Health integration, automating prior authorization workflows for high-volume eye care procedures and specialty medications.

Revenue cycle directors and prior authorization coordinators in ophthalmology practices face unique challenges when managing specialty benefit management requirements. Integrating with AIM Specialty Health, a Carelon (Elevance) company, is crucial for securing approvals for many advanced eye care treatments. Klivira's platform is engineered to navigate these specific requirements, reducing administrative burden and accelerating patient access to care.

Navigating AIM Specialty Health's Role in Ophthalmology Prior Authorization

AIM Specialty Health, as a specialty benefit manager for Carelon (Elevance), plays a significant role in reviewing and approving high-cost ophthalmology services. This includes critical treatments like anti-VEGF injections, premium intraocular lenses (IOLs), and specific surgical procedures. Effective integration ensures that your clinic's PA submissions align with payer policies and clinical necessity criteria, minimizing delays and denials.

Key Ophthalmology PA Triggers Managed by AIM Specialty Health

  • Anti-VEGF intravitreal injections: Aflibercept (Eylea, Eylea HD), ranibizumab (Lucentis), faricimab (Vabysmo), brolucizumab (Beovu), and bevacizumab (off-label)
  • Cataract surgery with premium IOL or specific lens technology
  • Glaucoma surgical procedures: Micro-invasive glaucoma surgery (MIGS), trabeculectomy, tube shunts
  • Corneal procedures: DSAEK, DMEK endothelial keratoplasty, corneal cross-linking
  • Oculoplastic procedures: Blepharoplasty for visual-field-affecting ptosis, ectropion/entropion repair

Meeting Documentation Requirements and Clinical Guidelines

Ophthalmology prior authorizations, especially those managed by AIM Specialty Health, heavily rely on precise documentation conforming to clinical guidelines like the AAO Preferred Practice Patterns. For anti-VEGF injections, this involves diagnosis confirmation via OCT, visual acuity, and prior treatment response. Premium IOLs require patient acknowledgment of out-of-pocket costs, while oculoplastic procedures demand visual field tests and photographs to establish medical necessity.

Streamlining Chronic Anti-VEGF Injection Cycles

Many retina patients require ongoing anti-VEGF injections, necessitating periodic re-authorization with updated response documentation. This chronic nature creates a high-volume, recurring PA workflow. Klivira's platform automates the submission of required clinical data, including OCT findings and visual acuity, and manages biosimilar substitution routing per payer policy, ensuring continuous care with minimal administrative overhead.

Klivira's Approach to Ophthalmology AIM Specialty Health Integration

Klivira connects directly with your EMR via standards like SMART on FHIR, extracting the necessary clinical data for AIM Specialty Health submissions. Our platform leverages AAO-guideline-aware logic to pre-populate X12 278 or ePA requests, facilitating rapid submission and tracking. This automation addresses the high volume of clinic-injection encounters and the nuanced cosmetic-vs-medical determination for oculoplastics, enhancing efficiency across your prior authorization workflow.

Frequently asked questions

What ophthalmology procedures typically require prior authorization through AIM Specialty Health?

Common procedures requiring prior authorization through AIM Specialty Health include anti-VEGF injections for conditions like wet AMD, premium intraocular lenses for cataract surgery, various glaucoma surgical procedures (e.g., MIGS), and oculoplastic procedures such as blepharoplasty when medically necessary.

How does Klivira handle anti-VEGF re-authorizations for chronic conditions?

Klivira automates the re-authorization process for chronic anti-VEGF injection cycles. Our platform tracks prior authorization expiration dates, prompts for updated clinical documentation such as OCT findings and visual acuity, and facilitates the submission of new requests to AIM Specialty Health, ensuring continuous approval for ongoing patient treatment.

What documentation is critical for oculoplastic procedures managed by AIM Specialty Health?

For oculoplastic procedures like blepharoplasty, critical documentation for AIM Specialty Health includes visual field tests demonstrating a field defect, along with clinical photographs. These are essential to establish medical necessity and differentiate functional procedures from cosmetic ones, aligning with payer policy requirements.

Can Klivira integrate with our EMR to submit PA requests to AIM Specialty Health?

Yes, Klivira is designed for seamless integration with major EMR systems using industry standards like SMART on FHIR. This allows for automated extraction of relevant patient demographics and clinical data, which is then used to pre-populate and submit prior authorization requests directly to AIM Specialty Health via X12 278 or ePA channels.

How does Klivira address biosimilar substitution requirements for anti-VEGF drugs?

Klivira incorporates payer-specific policies regarding biosimilar substitution for anti-VEGF drugs into its workflow. The platform can route prior authorization requests based on these policies, prompting for biosimilar use when required or providing the necessary clinical justification for brand-name medications, helping to prevent denials related to formulary compliance.

Related coverage

Other ophthalmology prior auth workflows

Ready to automate this workflow for this specialty?

See how Klivira automates prior authorizations for your team.

Request a demo